EHA 2021 | Adverse events associated with BTK inhibitor therapy in NHL
Nirav Niranjan Shah
• 14 Jun 2021
Nirav N. Shah, MD, Medical College of Wisconsin, Brookfield, WI, talks on adverse events associated with BTK inhibitor therapy. Ibrutinib, acalabrutinib and zanubrutinib are all BTK inhibitors used in the treatment of non-Hodgkin lymphoma. Dr Shah reports that cardiac toxicities are associated with BTK inhibitor therapy, in particular with ibrutinib, and comments on the need to develop drugs which minimise the risk of cardiac toxicities. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Nirav N. Shah, MD, has participated in consultancy work and advisory board with Lily Pharmaceuticals.
